Description: Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Home Page: www.daewonpharm.com
386 Cheonhodae-ro
Seoul,
South Korea
Phone:
82 2 2204 7000
Officers
| Name | Title |
|---|---|
| Mr. Seungyeol Baek | Vice Chairman, Chief Exec. Officer and Pres |
| Je-Ho Kim | Sr. Managing Director |
| Joong-Hyun Shin | Managing Director |
| Bon-Am Gu | Sr. Managing Director |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7259 |
| Price-to-Sales TTM: | 0.9 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1034 |